Here are 11 drugs with potential safety risks, according to a new Food and Drug Administration report.
The list contains drugs identified by the FDA's Adverse Event Reporting System from October to December 2016.
1. Contrave extended-release tablets may cause a lack of consciousness in patients. The agency is evaluating the need for regulatory action.
2. Coumadin, Eliquis, Pradaxa, Savaysa and Xarelto can cause menorrhagia — meuntstral periods with prolonged or abnormally heavy bleeding. The FDA decided no action is needed at this time.
3. Depo-Medrol, Depo-Provera and Depo-Provera Cl use led to medication errors. The FDA revised the drugs' labeling to better differentiate between Depo-Medrol and Depo-Provera products.
4. Diabeta tablets can cause skin reactions in some patients. The FDA updated the drug adverse reactions section of the drug's label to include bullous reactions, erythema multiforme and exfoliative dermatitis.
5. Imbruvica capsules can lead to pneumocystis jirovecii pneumonia. The agency updated the warnings and precautions section of the drug's label to include this disease.
6. Nitropress injections can cause carboxyhemoglobinemia, or a high concentration of carbon monoxide in the blood. The agency is evaluating the need for regulatory action.
7. Northera capsules can lead to cerebrovascular accident, or stroke. The warnings and precautions section, as well as the adverse reactions section, of the drug's labeling were updated to include information about strokes. The FDA is also evaluating the need for further regulatory action.
8. The injectable form of Nucala can cause anaphylaxis. The FDA updated the warnings and precautions section for the labeling to include this risk.
9. Opsumit tablets can cause fluid overload, a condition in which there is too much fluid in the blood. The agency updated the drug label's warnings and precautions section to include information about fluid retention.
10. Otezia tablets can cause diarrhea, nausea and vomiting in patients. The FDA is evaluating the need for regulatory action.
11. The injectable form of Tanzeum can cause user errors when administrating the medication via the Tanzeum pen. The FDA is evaluating the need for regulatory action.
More articles on supply chain:
Boston Scientific to buy Swiss devicemaker for $435M
How SSM Health's pharmacy concierge program helps patients manage high drug costs
Sanofi agrees to pay $20M for overcharging VA for vaccines: 4 things to know